Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice

Platelet-derived growth factor-BB accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells

(2013) Jiwen Cheng et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk

(2012) Karl Staser et al.   JOURNAL OF CLINICAL INVESTIGATION

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice

(2012) Tiffany Chang et al.   JOURNAL OF CLINICAL INVESTIGATION

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors

(2012) Walter J. Jessen et al.   JOURNAL OF CLINICAL INVESTIGATION

Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate

(2011) A. Schindeler et al.   JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME

The Haploinsufficient Hematopoietic Microenvironment Is Critical to the Pathological Fracture Repair in Murine Models of Neurofibromatosis Type 1

(2011) Xiaohua Wu et al.   PLoS One

Erk1 Positively Regulates Osteoclast Differentiation and Bone Resorptive Activity

(2011) Yongzheng He et al.   PLoS One

Bone marrow-derived mesenchymal stem cells and the tumor microenvironment

(2010) Scott A. Bergfeld et al.   CANCER AND METASTASIS REVIEWS

Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts

(2010) Weixi Wang et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin

(2008) Mateusz Kolanczyk et al.   BMC Medicine

Models of tibial fracture healing in normal and Nf1‐deficient mice

(2008) Aaron Schindeler et al.   JOURNAL OF ORTHOPAEDIC RESEARCH

Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type andNf1 haploinsufficient mice

(2007) Aaron Schindeler et al.   JOURNAL OF ORTHOPAEDIC RESEARCH